Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stake Reduced by Bellevue Group AG

Bellevue Group AG decreased its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 95.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,046 shares of the company’s stock after selling 425,358 shares during the period. Bellevue Group AG’s holdings in Apellis Pharmaceuticals were worth $549,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in APLS. Tidal Investments LLC acquired a new position in Apellis Pharmaceuticals in the first quarter worth approximately $266,000. Comerica Bank boosted its stake in shares of Apellis Pharmaceuticals by 500.7% during the 1st quarter. Comerica Bank now owns 8,163 shares of the company’s stock worth $480,000 after acquiring an additional 6,804 shares in the last quarter. DNB Asset Management AS grew its holdings in shares of Apellis Pharmaceuticals by 31.4% in the 2nd quarter. DNB Asset Management AS now owns 7,972 shares of the company’s stock worth $306,000 after acquiring an additional 1,904 shares during the last quarter. CWM LLC raised its position in shares of Apellis Pharmaceuticals by 299.9% during the second quarter. CWM LLC now owns 4,151 shares of the company’s stock worth $159,000 after purchasing an additional 3,113 shares during the period. Finally, Simplicity Wealth LLC lifted its holdings in shares of Apellis Pharmaceuticals by 0.6% during the second quarter. Simplicity Wealth LLC now owns 78,746 shares of the company’s stock valued at $3,021,000 after purchasing an additional 499 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Insider Activity at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. This trade represents a 27.01 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 6.80% of the stock is owned by company insiders.

Apellis Pharmaceuticals Stock Down 0.6 %

APLS opened at $33.93 on Monday. The company has a market capitalization of $4.22 billion, a PE ratio of -16.71 and a beta of 0.87. The business has a 50-day moving average of $28.72 and a 200-day moving average of $35.25. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $24.34 and a fifty-two week high of $73.80. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. Apellis Pharmaceuticals’s revenue was up 78.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.17) earnings per share. Equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on APLS shares. Oppenheimer dropped their price target on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Needham & Company LLC dropped their target price on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Citigroup cut their price target on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. UBS Group decreased their price objective on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Finally, William Blair assumed coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating on the stock. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $49.94.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).